Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

34
My Dividend Growth Portfolio - Q2 2018 Summary

2018-07-19 seekingalpha
I believe that someone who writes about financial assets should share his main holdings with his readers.
LMT FB GD GIS TXN XOM TWX UTX GOOG KMB K TWC GOOGL AAPL KHC SBUX ABBV MSFT ADM OHI MMP PFE ABBV

0
Buy This Dividend Aristocrat For 10%+ Annual Returns

2018-07-18 seekingalpha
Kimberly-Clark stock has declined over 10% so far in 2018. Negative sentiment is fueled by rising raw materials costs.
KMB

15
Can Savings Keep Kimberly-Clark (KMB) Afloat in Q2 Earnings?

2018-07-18 zacks
Kimberly-Clark Corporation (KMB - Free Report) is slated to release second-quarter 2018 results on Jul 24. This consumer goods company has a mixed record of earnings surprises in the trailing four quarters. Let’s see how things are placed ahead of the upcoming quarterly results. Will Cost-Cutting & Other Efforts Fuel Q2 Performance? Kimberly-Clark has been quite keen on reducing costs through its Focus on Reducing Costs Everywhere program or FORCE.
GEC GE KMB.WI GNE KMB KCDMY SAM BGS

25
Watchlist July 2018

2018-07-12 seekingalpha
It's time for the monthly watchlist report. As always, you can find the updated info at any time here Dividend Income Spreadsheet and the Portfolio Spreadsheet.
SOJA SO ENB PM HRL D IDTVF SBUX ENB KMB MO

46
10 Top 'Safer' Dividend Aristocrats Show 12.5-32.9% Gains Per July Audit

2018-07-12 seekingalpha
41 of 53 S&P 500 Dividend Aristocrats stocks were deemed "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields 7/9/18.
GD KMB SWK PEP JNJ CINF CVX ITW DOV ABBV ABBV LEG MCD

58
Top 10 Of 53 Dividend Aristocrats Yield 3.4%-6.2% In July Update

2018-07-11 seekingalpha
The 53 Aristocrats stocks represent all 11 Morningstar sectors. Broker target top 10 net gains ranged from 12.8% to 20.6%.
APD XOM WBA KMB PEP JNJ CVX DOV ABBV CAH ED ABBV MCD

109
Sharing My 2018 First Half Performance

2018-07-09 seekingalpha
I currently manage three portfolios and I share first half 2018 performance. The "High Octane" returned 10.6%, "Buy and Hold" 7.9%, and "Conservative" 7.4%.
SMRT ICON HSYFB GNC M RRL KMB RRS CGC AR RGRLF RRC TWMJF RGRYY PEP WEED HSY

32
5 Dividend Aristocrat ETFs for a Growing Retirement Income

2018-07-06 investorplace
The average retirement lasts for 18 years in the United States. Hence, when investing for retirement, investors need to consider how inflation will affect their income. Allocations into retirement stocks should be set with income in mind.
FOJCF O.PRF O CSL OPRF KMB KCDMY NNN.PRD NNN.PRF NNN.PRE FOJCY T KMB.WI TROW ABBV CFR MCD NNN ABBV

64
Your Daily Pharma Scoop: Eagle Gets New Patent, Ocular Refiles NDA, Antibe's Phase 2b Data Announced

2018-07-05 seekingalpha
Discussion: Eagle Pharmaceuticals Inc. (EGRX) is a specialty pharmaceutical company focused on developing and commercializing injectable products for oncology and critical care segments. The lead candidate of the company, Bendeka (bendamustine hydrochloride), received the U.S. Patent No. 10,010,533. The patent covers the drug’s use in blood cancer. The IP of the company now goes up to 15 patents. Teva Pharma (NYSE:TEVA) owns exclusive U.
OCUL ASLN EGRX ATBPF SRNE TEVA TTNP KMB AVXL ATE

0
UPDATE 1-Mexico's business bosses praise Lopez Obrador after testy campaign

2018-07-04 reuters
MEXICO CITY (Reuters) - Mexico’s business elite had warm words for president-elect Andres Manuel Lopez Obrador on Wednesday after he assured them he respected private enterprise, in contrast to jibes in the campaign that some tycoons belonged to a “mafia of power.”
KMB.WI KCDMY KMB

93
July 2018 Stock Considerations

2018-07-02 seekingalpha
Here we are with another installment of my "stock considerations" for the upcoming month. With the first week of trading upon us in July, it is time, once again, to lay out a plan for my potential stock pick(s) for the month. As many of you already know, I make sure to purchase at least one stock every single month, no matter where we are in a business or macroeconomic cycle. The goal of every long-term dividend growth investor is to remain consistent with their buys and try not to attempt to time the market and wait for the "best" possible time to invest.
SOJA HCN PM GIS HCP WELL.PRI LTC SBRA WELL CAH ED JCI SBRAP VTR SO GE GEC D HCN.PRJ KMB HCN.PRI PEP KHC GNE SBUX CLX

5
Conservative PA: Blue Chip Series - Kimberly-Clark

2018-06-29 seekingalpha
Kimberly-Clark is trading at roughly 15X FY 2018 Adjusted E.P.S. (mid-point) guidance of $7.05 per share.
GIS KMB

20
32 'Safer' Dividend Consumer Defensive Top Yield Stocks Projected To June, 2019

2018-06-28 seekingalpha
32 of 86 top yield Consumer Defensive stocks were tagged "safer" because they showed positive annual-returns, and free cash-flow yields greater than their dividend yields.
PM BUD TATYY WHGRF SLCJY AHBIF BATS 4162 KMB WHGLY WGHPY SLCJF

27
Recent Stock Purchase II June 2018

2018-06-27 seekingalpha
The last time I made two buy tranches in any one month was back in February of this year. I guess seeing the market continue on its volatile trajectory prompted me to make additional buys before June officially expires. On another note, my broker ShareBuilder, formerly ING, formerly CapitalOne Investing, has been acquired by E-Trade, and before the assets are moved over later this year, it was announced that all dividend reinvestment will be suspended along with ShareBuilder Investment Plans in July.
CAH KMB

145
Turning Challenge Into Opportunity

2018-06-25 seekingalpha
By reorganizing to meet clients’ ever changing needs, this advertising giant has continued to grow profits faster than investors realize.
FB AMGN F WPP NLSN IPG KMB INTU T JNJ GOOGL OMC CCO HSBC MCD

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to KMB / Kimberly-Clark Corp. on message board site Silicon Investor.

Kimberly-Clark Corp. (NYSE:KMB)
CUSIP: 494368103